Alteration of CD39+Foxp3+CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment

作者：Pant Anudeep B; Wang Yan; Mielcarz Daniel W; Kasper Eli J; Telesford Kiel M; Mishra Megan; Haque Azizul^*; Channon Jacqueline Y; Kasper Lloyd H; Begum Haque Sakhina

来源：Journal of Neuroimmunology, 2017, 303: 22-30.

DOI：10.1016/i.jneuroim.2016.12.010

• Experimental autoimmune encephalomyelitis
• Multiple sclerosis
• Therapeutic
• Anti-CD52 mAb
• CD39+T regulatory cells
• Cytokine

While examining the therapeutic value of anti-CD52 antibody against EAE/MS, we identified a unique subset of CD39+ Tregs in repopulating GALT tissues, a major lymphoid reservoir, which was accompanied by amelioration of disease. Furthermore, anti-CD52 treatment leads to increased expression of BDNF, IL-10, and SMAD3 in the brains of EAE mice. This condition is associated with suppression of IL-17, a critical inflammatory factor in EAE/MS progression. Additionally, we found elevated levels of CD4+ CD39+ Tregs in PBMCs of RRMS patients treated with humanized anti-CD52 mAb. Thus, anti-CD52 can affect multiple immune mediated pathways involved in the pathogenesis of EAE/MS.

• 出版日期2017-2-15